Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Prognostic risk factors in advanced Hodgkin's lymphoma

Prognostic risk factors in advanced Hodgkin's lymphoma 277 56 56 6 6 M. Loeffler M. Pfreundschuh D. Hasenclever E. Hiller H. Gerhartz W. Wilmanns R. Rohloff U. Rühl G. Kühn R. Fuchs H. Kirchner J. Teichmann W. Schoppe S. Petsch W. Wilhelmy P. Worst K. H. Pflüger T. Hecht H. Bartels W. Gassmann G. Krüger G. Schmitz W. Oertel V. Diehl chairman Hodgkin Studiensekretariat Josef-Stelzmann-Strasse 9 D-5000 Köln 41 Federal Republic of Germany Summary In a national multicentre trial in the FRG patients with Hodgkin's lymphoma in stages CS/PS III B/IV were entered into the HD 3 protocol and received induction chemotherapy with 3× (COPP+ABVD). Patients in complete remission (CR) received consolidation therapy by either radiotherapy (20 Gy IF) or chemotherapy (COPP+ABVD). Patients not in CR received salvage therapy (40 Gy in case of persisting nodal disease, else 4× CEVD chemotherapy). Between July 1983 and May 1987 230 untreated patients aged 15 to 60 qualified for this HD 3 protocol. This analysis is based on the first 137 patients evaluable for response. Of these, 86 (63%) achieved CR after induction chemotherapy. Including salvage therapy a total of 104 patients (76%) achieved CR. Univariate and multivariate prognostic risk factor analyses were performed using freedom from treatment failure (FFTF) as endpoint. Sex, age, splenectomy, bone marrow, liver and bone involvement had no prognostic impact nor had stage according to the Ann Arbor classification. In contrast, a pretreatment erythrocyte sedimentation rate (ESR) above 80 mm/h and a serum alkaline phosphatase (AP) above 230 IU/ml appeared as significant risk factors ( p <0.01, relative risk 2.3). The two parameters were not independent. Comparing a group A (ESR ≤ 80 and AP ≤ 230) versus a pooled group B (ESR>80 and/or AP>230) increased the difference ( p <0.001, relative risk of 2.8) which was also significant for survival ( p <0.04). http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annals of Hematology Springer Journals

Prognostic risk factors in advanced Hodgkin's lymphoma

Download PDF
9 pages

Loading next page...
 
/lp/springer-journals/prognostic-risk-factors-in-advanced-hodgkin-s-lymphoma-bsJIIPvyC8

References (12)

Publisher
Springer Journals
Copyright
Copyright © 1988 by Springer-Verlag
Subject
Medicine & Public Health; Hematology; Oncology
ISSN
0939-5555
eISSN
1432-0584
DOI
10.1007/BF00320290
Publisher site
See Article on Publisher Site

Abstract

277 56 56 6 6 M. Loeffler M. Pfreundschuh D. Hasenclever E. Hiller H. Gerhartz W. Wilmanns R. Rohloff U. Rühl G. Kühn R. Fuchs H. Kirchner J. Teichmann W. Schoppe S. Petsch W. Wilhelmy P. Worst K. H. Pflüger T. Hecht H. Bartels W. Gassmann G. Krüger G. Schmitz W. Oertel V. Diehl chairman Hodgkin Studiensekretariat Josef-Stelzmann-Strasse 9 D-5000 Köln 41 Federal Republic of Germany Summary In a national multicentre trial in the FRG patients with Hodgkin's lymphoma in stages CS/PS III B/IV were entered into the HD 3 protocol and received induction chemotherapy with 3× (COPP+ABVD). Patients in complete remission (CR) received consolidation therapy by either radiotherapy (20 Gy IF) or chemotherapy (COPP+ABVD). Patients not in CR received salvage therapy (40 Gy in case of persisting nodal disease, else 4× CEVD chemotherapy). Between July 1983 and May 1987 230 untreated patients aged 15 to 60 qualified for this HD 3 protocol. This analysis is based on the first 137 patients evaluable for response. Of these, 86 (63%) achieved CR after induction chemotherapy. Including salvage therapy a total of 104 patients (76%) achieved CR. Univariate and multivariate prognostic risk factor analyses were performed using freedom from treatment failure (FFTF) as endpoint. Sex, age, splenectomy, bone marrow, liver and bone involvement had no prognostic impact nor had stage according to the Ann Arbor classification. In contrast, a pretreatment erythrocyte sedimentation rate (ESR) above 80 mm/h and a serum alkaline phosphatase (AP) above 230 IU/ml appeared as significant risk factors ( p <0.01, relative risk 2.3). The two parameters were not independent. Comparing a group A (ESR ≤ 80 and AP ≤ 230) versus a pooled group B (ESR>80 and/or AP>230) increased the difference ( p <0.001, relative risk of 2.8) which was also significant for survival ( p <0.04).

Journal

Annals of Hematology – Springer Journals

Published: Jun 1, 1988

There are no references for this article.